What is the current valuation of the Cancer Gene Therapy Market as of 2024?

The Cancer Gene Therapy Market was valued at 8.05 USD Billion in 2024. Read More

What is the projected market size for the Cancer Gene Therapy Market by 2035?

The market is projected to reach 32.01 USD Billion by 2035. Read More

What is the expected CAGR for the Cancer Gene Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Cancer Gene Therapy Market during 2025 - 2035 is 13.37%. Read More

Which therapeutic approach segments are expected to show significant growth?

The Gene Transfer segment is projected to grow from 2.0 USD Billion to 8.0 USD Billion by 2035. Read More

What are the leading types of therapy in the Cancer Gene Therapy Market?

In-Vivo Therapy is anticipated to expand from 3.0 USD Billion to 12.0 USD Billion by 2035. Read More

Which delivery method is expected to dominate the market?

Viral Vectors are likely to lead the market, growing from 3.22 USD Billion to 12.8 USD Billion by 2035. Read More

What are the key diseases targeted by cancer gene therapies?

Lung Cancer is projected to grow from 1.8 USD Billion to 7.2 USD Billion by 2035. Read More

Who are the major players in the Cancer Gene Therapy Market?

Key players include Novartis, Gilead Sciences, and Bristol-Myers Squibb. Read More

What is the growth potential for immunotherapy in the Cancer Gene Therapy Market?

Immunotherapy is expected to increase from 2.55 USD Billion to 10.01 USD Billion by 2035. Read More

How does the market for leukemia treatments compare to other cancers?

Leukemia treatments are projected to grow from 1.2 USD Billion to 4.8 USD Billion by 2035, indicating a robust market presence. Read More

Cancer Gene Therapy Market

ID: MRFR/Pharma/40603-HCR 200 Pages Satyendra Maurya Last Updated: September 17, 2026

Cancer Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Approach (Gene Editing, Gene Transfer, Oncolytic Virus Therapy, Gene Silencing, Immunotherapy), By Target Disease (Breast Cancer, Lung Cancer, Leukemia, Colorectal Cancer, Prostate Cancer), By Types of Therapy (Ex-Vivo Therapy, In-Vivo Therapy, Combination Therapy), By Delivery Method (Viral Vectors, Plasmid DNA, Nanoparticles) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Cancer Gene Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)13.37%

2024 Market Size$ 8.05 Billion

2025 Market Size$ 9.13 Billion

2035 Market Size$ 32.01 Billion

Key Players

Novartis

Gilead Sciences

Bristol-Myers Squibb

Amgen

Sangamo Therapeutics

Bluebird Bio

Trends

Technological Advancements in Gene Editing
Personalized Medicine Trends
Collaborative Research Initiatives

Opportunities

Rising Incidence of Cancer
Increased Investment in Cancer Research
Advancements in Gene Editing Technologies

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapeutic Approach (USD Billion)
  1. 4.1.1 Gene Editing
  2. 4.1.2 Gene Transfer
  3. 4.1.3 Oncolytic Virus Therapy
  4. 4.1.4 Gene Silencing
  5. 4.1.5 Immunotherapy
2. 4.2 Healthcare, BY Target Disease (USD Billion)
  1. 4.2.1 Breast Cancer
  2. 4.2.2 Lung Cancer
  3. 4.2.3 Leukemia
  4. 4.2.4 Colorectal Cancer
  5. 4.2.5 Prostate Cancer
3. 4.3 Healthcare, BY Type of Therapy (USD Billion)
  1. 4.3.1 Ex-Vivo Therapy
  2. 4.3.2 In-Vivo Therapy
  3. 4.3.3 Combination Therapy
4. 4.4 Healthcare, BY Delivery Method (USD Billion)
  1. 4.4.1 Viral Vectors
  2. 4.4.2 Plasmid DNA
  3. 4.4.3 Nanoparticles
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bluebird Bio (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Spark Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Celyad Oncology (BE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Zymeworks (CA)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC APPROACH
4. 6.4 US MARKET ANALYSIS BY TARGET DISEASE
5. 6.5 US MARKET ANALYSIS BY TYPE OF THERAPY
6. 6.6 US MARKET ANALYSIS BY DELIVERY METHOD
7. 6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC APPROACH
8. 6.8 CANADA MARKET ANALYSIS BY TARGET DISEASE
9. 6.9 CANADA MARKET ANALYSIS BY TYPE OF THERAPY
10. 6.10 CANADA MARKET ANALYSIS BY DELIVERY METHOD
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC APPROACH
13. 6.13 GERMANY MARKET ANALYSIS BY TARGET DISEASE
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE OF THERAPY
15. 6.15 GERMANY MARKET ANALYSIS BY DELIVERY METHOD
16. 6.16 UK MARKET ANALYSIS BY THERAPEUTIC APPROACH
17. 6.17 UK MARKET ANALYSIS BY TARGET DISEASE
18. 6.18 UK MARKET ANALYSIS BY TYPE OF THERAPY
19. 6.19 UK MARKET ANALYSIS BY DELIVERY METHOD
20. 6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC APPROACH
21. 6.21 FRANCE MARKET ANALYSIS BY TARGET DISEASE
22. 6.22 FRANCE MARKET ANALYSIS BY TYPE OF THERAPY
23. 6.23 FRANCE MARKET ANALYSIS BY DELIVERY METHOD
24. 6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
25. 6.25 RUSSIA MARKET ANALYSIS BY TARGET DISEASE
26. 6.26 RUSSIA MARKET ANALYSIS BY TYPE OF THERAPY
27. 6.27 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD
28. 6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC APPROACH
29. 6.29 ITALY MARKET ANALYSIS BY TARGET DISEASE
30. 6.30 ITALY MARKET ANALYSIS BY TYPE OF THERAPY
31. 6.31 ITALY MARKET ANALYSIS BY DELIVERY METHOD
32. 6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC APPROACH
33. 6.33 SPAIN MARKET ANALYSIS BY TARGET DISEASE
34. 6.34 SPAIN MARKET ANALYSIS BY TYPE OF THERAPY
35. 6.35 SPAIN MARKET ANALYSIS BY DELIVERY METHOD
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC APPROACH
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TARGET DISEASE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TYPE OF THERAPY
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC APPROACH
42. 6.42 CHINA MARKET ANALYSIS BY TARGET DISEASE
43. 6.43 CHINA MARKET ANALYSIS BY TYPE OF THERAPY
44. 6.44 CHINA MARKET ANALYSIS BY DELIVERY METHOD
45. 6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
46. 6.46 INDIA MARKET ANALYSIS BY TARGET DISEASE
47. 6.47 INDIA MARKET ANALYSIS BY TYPE OF THERAPY
48. 6.48 INDIA MARKET ANALYSIS BY DELIVERY METHOD
49. 6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC APPROACH
50. 6.50 JAPAN MARKET ANALYSIS BY TARGET DISEASE
51. 6.51 JAPAN MARKET ANALYSIS BY TYPE OF THERAPY
52. 6.52 JAPAN MARKET ANALYSIS BY DELIVERY METHOD
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC APPROACH
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TARGET DISEASE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TYPE OF THERAPY
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD
57. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
58. 6.58 MALAYSIA MARKET ANALYSIS BY TARGET DISEASE
59. 6.59 MALAYSIA MARKET ANALYSIS BY TYPE OF THERAPY
60. 6.60 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD
61. 6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC APPROACH
62. 6.62 THAILAND MARKET ANALYSIS BY TARGET DISEASE
63. 6.63 THAILAND MARKET ANALYSIS BY TYPE OF THERAPY
64. 6.64 THAILAND MARKET ANALYSIS BY DELIVERY METHOD
65. 6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC APPROACH
66. 6.66 INDONESIA MARKET ANALYSIS BY TARGET DISEASE
67. 6.67 INDONESIA MARKET ANALYSIS BY TYPE OF THERAPY
68. 6.68 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD
69. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC APPROACH
70. 6.70 REST OF APAC MARKET ANALYSIS BY TARGET DISEASE
71. 6.71 REST OF APAC MARKET ANALYSIS BY TYPE OF THERAPY
72. 6.72 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC APPROACH
75. 6.75 BRAZIL MARKET ANALYSIS BY TARGET DISEASE
76. 6.76 BRAZIL MARKET ANALYSIS BY TYPE OF THERAPY
77. 6.77 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD
78. 6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC APPROACH
79. 6.79 MEXICO MARKET ANALYSIS BY TARGET DISEASE
80. 6.80 MEXICO MARKET ANALYSIS BY TYPE OF THERAPY
81. 6.81 MEXICO MARKET ANALYSIS BY DELIVERY METHOD
82. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC APPROACH
83. 6.83 ARGENTINA MARKET ANALYSIS BY TARGET DISEASE
84. 6.84 ARGENTINA MARKET ANALYSIS BY TYPE OF THERAPY
85. 6.85 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC APPROACH
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET DISEASE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF THERAPY
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC APPROACH
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TARGET DISEASE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF THERAPY
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC APPROACH
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TARGET DISEASE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF THERAPY
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD
99. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC APPROACH
100. 6.100 REST OF MEA MARKET ANALYSIS BY TARGET DISEASE
101. 6.101 REST OF MEA MARKET ANALYSIS BY TYPE OF THERAPY
102. 6.102 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY THERAPEUTIC APPROACH, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY THERAPEUTIC APPROACH, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY TYPE OF THERAPY, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY TYPE OF THERAPY, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.2.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.2.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.3.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.3.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.3.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.4.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.4.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.4.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.5.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.5.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.5.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.6.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.6.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.6.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.7.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.7.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.7.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.8.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.8.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.8.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.9.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.9.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.9.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.10.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.10.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.10.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.11.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.11.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.11.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.12.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.12.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.12.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.13.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.13.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.13.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.14.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.14.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.14.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.15.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.15.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.15.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.16.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.16.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.16.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.17.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.17.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.17.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.18.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.18.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.18.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.19.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.19.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.19.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.20.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.20.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.20.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.21.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.21.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.21.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.22.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.22.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.22.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.23.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.23.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.23.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.24.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.24.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.24.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.25.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.25.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.25.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.26.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.26.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.26.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.27.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.27.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.27.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.28.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.28.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.28.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.29.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.29.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.29.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY THERAPEUTIC APPROACH, 2025-2035 (USD Billion)
  2. 7.30.2 BY TARGET DISEASE, 2025-2035 (USD Billion)
  3. 7.30.3 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  4. 7.30.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Enquiry

Customize Report

Cancer Gene Therapy Market Segmentation

Cancer Gene Therapy Market By Therapeutic Approach (USD Billion, 2025-2035)

Gene Editing
Gene Transfer
Oncolytic Virus Therapy
Gene Silencing
Immunotherapy

Cancer Gene Therapy Market By Target Disease (USD Billion, 2025-2035)

Breast Cancer
Lung Cancer
Leukemia
Colorectal Cancer
Prostate Cancer

Cancer Gene Therapy Market By Type of Therapy (USD Billion, 2025-2035)

Ex-Vivo Therapy
In-Vivo Therapy
Combination Therapy

Cancer Gene Therapy Market By Delivery Method (USD Billion, 2025-2035)

Viral Vectors
Plasmid DNA
Nanoparticles

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”